Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.
Also called NCT06723002
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT06723002
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06723002. Randomized; double masking; primary purpose treatment. Start 2024-12-01 (anticipated); primary completion 2025-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome
- Acronym
- ACS_ATHEROLIV
- Condition
- Acute Coronary Syndrome (ACS)
- Condition
- Reactive Hyperemia
- Condition
- Endothelial Dysfunction
- Intervention (Drug)
- Atherolive 500mg/day
- Intervention (Drug)
- Atherolive 1000/day
- Intervention (Drug)
- Placbo_Atherolive
- Lead sponsor
- University of Monastir
Record details
- Record id
cardio:ct-nct06723002- Content hash
d8066097093ee7275f1bde3b963fff582a2c397bef20e4c2f9b2e19de2582761